West Pharmaceutical Services stock is priced richly after a strong run, with a 62.0% 1 year gain sitting beside valuation checks that currently flag the shares as expensive rather than a clear bargain.

• Over the past 12 months, West Pharmaceutical Services has returned 62.0%, which puts extra focus on whether the current price already embeds high expectations.
• Analyst expectations for higher earnings and recent portfolio moves around the SmartDose platform can support the current valuation. However, any disappointment on future profitability or growth could put pressure on a stock that is already viewed as overvalued.
• On Simply Wall St's broader checks, West Pharmaceutical Services passes 0 out of 6 value tests. This means the stock currently leans expensive rather than screening as a clear value opportunity, as shown in its value score of 0.

The issue now is whether West Pharmaceutical Services' current share price offers enough potential upside to compensate for that rich valuation profile.

Is West Pharmaceutical Services Getting Expensive on Earnings?

The P/E ratio is a useful way to look at West Pharmaceutical Services because earnings remain a key focus for how the market values this business. West Pharmaceutical Services currently trades on a P/E of about 46.4x, compared with a Life Sciences industry average of roughly 37.5x and a peer group average of about 28.8x. That places the stock at a clear premium to both its sector and closer peers.

The fair P/E ratio implied by Simply Wall St’s model, which factors in the company’s profile and risks more directly, sits at about 22.3x. Against that benchmark, the current multiple is more than double what would be implied, suggesting investors are paying a high price for each dollar of earnings. Despite the recent optimism around West Pharmaceutical Services’ upcoming Q2 2026 earnings report, the market-multiple workup still indicates that the stock is pricing in very strong expectations.

On the P/E multiple, West Pharmaceutical Services currently appears to be trading at a higher earnings valuation than both peers and the modelled fair ratio.

The West Pharmaceutical Services Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around West Pharmaceutical Services and turn it into a set of clear, testable assumptions about future growth, margins and earnings that would need to play out for the stock to be worth materially more or less than today’s price. These narratives sit on the company’s Community page. Rather than relying on a single multiple or model output, each narrative lays out the underlying drivers behind its fair value view so you can compare those assumptions with actual results over time.

If you have a number driven view on whether West Pharmaceutical Services' upcoming earnings and SmartDose changes support today's valuation, consider sharing a Narrative with the Simply Wall St community. It can be a way to put your thesis on record and see how it holds up as new results and company updates come through.

Do you think there's more to the story for West Pharmaceutical Services? Head over to our Community to see what others are saying!

The Bottom Line

West Pharmaceutical Services now trades on earnings multiples that suggest the stock is overvalued relative to its industry and to a modelled fair ratio. That kind of premium can persist, but it leaves less room for error if earnings or SmartDose execution fall short of what the current price implies. From here, the key question is whether West Pharmaceutical Services can deliver the growth and profitability that keep investors comfortable paying such a rich P/E, or whether the market eventually reins in those expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.